Back
Compare AU
Compare DRUG vs. GGAB
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Betashares Geared Long Aus Gov Bond Complex ETF (GGAB). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | GGAB | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 74 | 0 |
Median incremental investment | $740.50 | $0 |
Median investment frequency | Monthly | N/A |
Median total investment | $1,783.28 | $0 |
Average age group | 26 - 35 | N/A |
Key Summary
DRUG | GGAB | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | GGAB.AX was created on 2023-12-04 by BetaShares. The fund's investment portfolio concentrates primarily on broad credit fixed income. The ETF currently has 3.46m in AUM and 1 holdings. The investment objective of the Betashares Geared Long Australian Government Bond Fund (hedge fund) is to provide Unitholders with geared long exposure to the returns of Australian Treasury Bonds with a term to maturity of approximately 10 years (10 Year Australian Treasury Bonds). |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | AUST 10Y BOND FUT MAR26 (0 %) AUD - AUSTRALIA DOLLAR (100.00 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | |
Management fee | 0.57 % | 0.99 % |
Key Summary
DRUG | GGAB | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.99 % |
Price | $8.85 | $19.59 |
Size | $179.004 million | $3.462 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 1.50 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 05/12/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | GGAB | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 74 | 0 |
Median incremental investment | $740.50 | $0 |
Median investment frequency | Monthly | N/A |
Median total investment | $1,783.28 | $0 |
Average age group | 26 - 35 | N/A |
Pros and Cons
DRUG | GGAB | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | GGAB |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |